1 证券代码：688139 证券简称：海尔生物 青岛海尔生物医疗股份有限公司 投资者关系活动记录表 编号：2022-006 | --- | --- | --- | --- | |-----------------------|---------------------------------------|---------|-----------------------------------------------------------| | | | | | | 投资者关系活动 | 特定对象调研 | □ | 分析师会议 | | 类别 | □媒体采访 | □ | 业绩说明会 | | | □新闻发布会 | □ | 路演活动 | | | □现场参观 | □ | 电话会议 | | | □其他 （请文字说明其他活动内容） | | | | 参与单位名称 | 共 157 构，参会机构名单详见附表。 | | | | 时间 | 2022 年 5 月 17 日— 6 | 月 17 | 日 | | 参会方式 | 电话会议、现场会议 | | | | 上市公司接待人 员姓名 | 董事会秘书黄艳莉、证券事务代表蒋宏建 | | | | ...

Financial Performance - The company's operating revenue for Q3 2022 reached ¥807,395,894.65, representing a year-on-year increase of 36.34%[7] - The net profit attributable to shareholders for Q3 2022 was ¥160,875,376.68, with a year-on-year increase of 28.59%[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥136,145,703.57, reflecting a year-on-year increase of 36.00%[7] - The company's operating revenue increased by 36.52% during the reporting period, driven by growth in both IoT solutions and traditional business segments[22] - Total operating revenue for the first three quarters of 2022 reached CNY 2,075,274,671.51, a 36.4% increase from CNY 1,520,143,956.41 in the same period of 2021[44] - Net profit for the third quarter of 2022 was CNY 464,543,504.50, down 33.7% from CNY 700,445,995.03 in the previous year[47] - The total comprehensive income attributable to the parent company was 463,660,821.15 CNY, a decrease from 722,641,850.20 CNY in the previous year, representing a decline of approximately 35.8%[49] - Basic and diluted earnings per share were both 1.46 CNY, down from 2.20 CNY in the same period last year, indicating a decrease of about 33.6%[49] Research and Development - Research and development expenses totaled ¥77,377,397.24 in Q3 2022, accounting for 9.58% of operating revenue, a decrease of 4.17 percentage points year-on-year[11] - Research and development expenses for the first three quarters amounted to CNY 211,246,026.69, an increase from CNY 174,004,095.97, representing a growth of 21.4%[44] Market Growth - The domestic market grew by 30.53% year-on-year, while the overseas market saw a growth of 54.02%[15] - The life sciences digital scenario revenue increased by 46.31% year-on-year, while the medical innovation digital scenario revenue grew by 29.52%[13] Assets and Liabilities - The total assets of the company at the end of Q3 2022 were ¥5,142,698,967.95, an increase of 4.96% compared to the end of the previous year[11] - As of September 30, 2022, the total assets of the company reached approximately RMB 5.14 billion, an increase from RMB 4.90 billion at the end of 2021, reflecting a growth of about 4.95%[36] - The company's current assets totaled approximately RMB 3.49 billion, compared to RMB 3.46 billion at the end of 2021, indicating a slight increase of around 0.70%[39] - The company's non-current assets totaled approximately RMB 1.66 billion, up from RMB 1.44 billion at the end of 2021, showing an increase of about 14.83%[39] - The total liabilities decreased to CNY 1,210,378,778.46 from CNY 1,261,079,904.20, reflecting a reduction of approximately 4.0%[44] - The company's total equity increased to CNY 3,932,320,189.49 from CNY 3,638,749,093.87, reflecting an increase of approximately 8.1%[44] Cash Flow - The cash flow from operating activities decreased by 56.30%, primarily due to an increase in cash payments for goods and services[27] - Cash inflow from operating activities totaled 1,958,373,149.95 CNY, compared to 1,894,103,983.24 CNY in the previous year, reflecting an increase of approximately 3.4%[53] - Net cash flow from operating activities was 193,535,402.24 CNY, a significant decrease of 56.3% from 442,839,649.28 CNY in the prior year[53] - Cash inflow from investment activities was 9,754,732,369.18 CNY, up from 5,001,698,658.93 CNY, marking an increase of approximately 94.5%[54] - The net cash flow from financing activities was -208,117,313.00 CNY, compared to -147,113,388.82 CNY in the previous year, indicating a decline of about 41.5%[54] Other Financial Metrics - The weighted average return on equity was 4.21%, an increase of 0.44 percentage points year-on-year[11] - The total comprehensive income decreased by 35.61%, mainly due to changes in net profit during the reporting period[26] - The company reported a significant decrease of 60.24% in notes receivable, mainly due to the maturity and acceptance of notes during the reporting period[22] - The company experienced a 44.44% decrease in taxes payable, mainly due to a reduction in income tax payable during the reporting period[22] - The company reported a foreign exchange impact on cash and cash equivalents of 32,144,292.63 CNY, compared to 8,681,857.50 CNY in the previous year, showing an increase of approximately 270.5%[54]

Financial Performance - Haier Biomedical reported a revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15%[19]. - The company achieved a net profit of RMB 300 million, up 20% compared to the same period last year[19]. - The company's operating revenue for the first half of the year reached ¥1,267,878,776.86, representing a year-on-year increase of 36.63% compared to ¥927,954,150.02 in the same period last year[26]. - The net profit attributable to shareholders of the listed company was ¥300,570,997.11, a decrease of 47.55% from ¥573,077,466.11 in the previous year[26]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 26.57% to ¥272,123,675.07 from ¥214,999,373.27 in the same period last year[29]. - Basic earnings per share decreased by 47.51% to ¥0.95 from ¥1.81 in the previous year[30]. - The weighted average return on net assets decreased by 10.81 percentage points to 8.12% from 18.93% in the previous year[30]. - The net cash flow from operating activities was ¥184,335,005.22, a decrease of 15.00% from ¥216,874,817.07 in the previous year[29]. - The company's net assets attributable to shareholders increased by 3.32% to ¥3,742,947,461.44 from ¥3,622,799,326.47 at the end of the previous year[29]. - The company confirmed stock incentive expenses during the reporting period, impacting net profit figures[31]. Market Expansion and Strategy - User data indicated a growth in active users by 25%, reaching a total of 500,000 users[19]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by 2025[19]. - Haier Biomedical is exploring potential acquisitions to enhance its product portfolio and market reach[19]. - The company has established a presence in over 130 countries and regions, serving thousands of end-users in the healthcare sector, including major hospitals and research institutions in China[43]. - The company has established nearly 200 domestic distribution networks and over 600 overseas distribution networks, serving over 500 after-sales service partners[125]. - The company's overseas business has seen rapid growth in Southeast Asia and South America, contributing to the local healthcare system upgrades[134]. Research and Development - Haier Biomedical is investing RMB 200 million in R&D for new product development, focusing on advanced biomedicine technologies[19]. - Research and development expenses accounted for 10.56% of operating revenue, an increase of 0.58 percentage points compared to 9.98% in the previous year[30]. - The total R&D investment reached approximately ¥133.87 million, a 44.61% increase compared to ¥92.57 million in the same period last year, with R&D expenses accounting for 10.56% of operating revenue[98]. - The company has applied for 178 new patents and obtained 126 authorizations in the first half of 2022, indicating a rapid increase in intellectual property achievements[89]. - The company has established an open R&D model, attracting top talent and collaborating with universities and research institutions to enhance its innovation capabilities[93]. - The company has led or participated in the drafting of several national standards, reinforcing its position as an industry leader in standard-setting[94]. Product Development and Innovation - The company has launched a new solar-powered vaccine storage solution, aiming to capture a significant share of the cold chain logistics market[19]. - The company has developed core technologies in automation, microbial culture, and rapid cooling centrifugation, enhancing its product offerings in laboratory solutions[42]. - The company has achieved significant technological breakthroughs in low-temperature storage, establishing a complete technical system that breaks foreign monopolies, and has received 22 provincial and national science and technology awards[68]. - The company has developed a low-temperature refrigeration system that maintains an internal temperature fluctuation of 0 degrees, ensuring long-term reliability without the use of lubricating oil[79]. - The company has introduced a mobile vaccination system that integrates IoT and cloud computing for comprehensive vaccine traceability and management[85]. - The company has developed a digital nucleic acid sampling system that enhances sampling efficiency and allows for contactless registration, reducing sampling time to just 10 seconds[92]. - The company has completed the development of a new generation of intelligent safety cabinets, focusing on the European and American market needs, and has obtained CE and NSF certifications[104]. Sustainability and Environmental Commitment - Haier Biomedical is committed to sustainability, with plans to reduce carbon emissions by 15% by 2025[19]. - The company has implemented measures to reduce carbon emissions through optimized production processes and resource allocation[171]. - The company has adopted environmentally friendly materials and technologies, including LBA foaming technology, to enhance sustainability[171]. - The company has received multiple energy-saving and environmental certifications for its products, including CQC and EPA certifications[171]. Financial Commitments and Governance - The company has committed to not transferring or entrusting the management of its pre-IPO shares for 36 months from the date of listing on the Shanghai Stock Exchange[176]. - The company and its major shareholders have made commitments regarding stock repurchase and measures to stabilize stock prices for three years post-listing[181]. - The company has outlined specific measures to address any potential dilution of returns for investors[181]. - The company has confirmed that all commitments related to the IPO have been fulfilled in a timely manner[176]. Operational Challenges and Risk Management - The management highlighted the importance of risk management strategies in navigating potential market challenges[19]. - The company is exposed to foreign exchange risks due to its export business, primarily settled in USD, and has strategies in place to mitigate these risks[149]. - The company aims to enhance its supply chain by optimizing transportation routes and expanding its supplier network to mitigate raw material supply risks[146].

Revenue and Profitability - The company's revenue for Q1 2022 was CNY 563,453,088.49, representing a year-on-year increase of 36.22%[6] - Net profit attributable to shareholders decreased by 72.96% to CNY 113,524,222.50, while the net profit after deducting non-recurring gains and losses increased by 7.53% to CNY 101,234,822.19[6] - The company's operating revenue increased by 36.22% due to high growth in both IoT solutions and traditional businesses[22] - The total profit decreased by 73.95%, influenced by the growth in operating scale and one-time gains from the disposal of joint ventures[22] - Basic earnings per share for Q1 2022 were ¥0.36, down from ¥1.32 in Q1 2021[45] Research and Development - The company's R&D investment totaled CNY 68,022,389.62, up 64.55% year-on-year, accounting for 12.07% of revenue, an increase of 2.08 percentage points[6] - Research and development expenses surged by 64.55%, reflecting ongoing investment in R&D projects[22] - R&D expenses in Q1 2022 amounted to ¥68,022,389.62, an increase of 64.5% from ¥41,339,082.29 in Q1 2021[43] Cash Flow and Liquidity - The company achieved a net cash flow from operating activities of CNY 97,673,285.67, a decrease of 21.34% year-on-year[9] - Cash and cash equivalents rose by 118.98%, primarily due to increased net cash inflow from investment activities[22] - Operating cash inflows totaled $590,285,019.47, a decrease of 15.6% from $699,312,434.03[49] - The net increase in cash and cash equivalents was $922,441,143.20, contrasting with a decrease of $790,412,666.82 in the prior period[51] - The ending balance of cash and cash equivalents stood at $1,669,686,010.00, up from $1,004,000,369.06[51] Market Expansion and Business Growth - The IoT solution business saw an impressive revenue growth of 88.42%, contributing to 35.33% of total revenue[12] - Revenue from the life sciences digital scenario grew by 46.78%, while revenue from medical innovation digital scenarios increased by 27.39%[12] - The company has expanded its market presence, adding 49 new channels in regions such as Africa, South America, and Southeast Asia, while enhancing local personnel in Europe and North America[16] - The newly launched biochemical incubator supports the expansion into genetic disease screening and microbial diagnostics, broadening the user base from biopharmaceutical companies to medical institutions[14] Financial Position - As of March 31, 2022, the company's total assets amounted to approximately CNY 4.96 billion, an increase from CNY 4.90 billion at the end of 2021, reflecting a growth of about 1.1%[34] - The company's cash and cash equivalents reached CNY 1.70 billion, significantly up from CNY 774.39 million in the previous year, indicating an increase of approximately 118%[34] - The company's accounts receivable increased to CNY 137.35 million from CNY 112.29 million, representing a growth of about 22.3% year-over-year[34] - The total current liabilities decreased slightly to CNY 1.12 billion from CNY 1.14 billion, showing a reduction of approximately 3.3%[37] - The company's long-term equity investments rose to CNY 115.26 million, up from CNY 113.19 million, marking an increase of about 1.8%[36] Employee Compensation and Expenses - The company reported a decrease in employee compensation liabilities to CNY 46.79 million from CNY 66.59 million, a reduction of about 29.8%[37] - Payments to employees increased to $125,522,642.75 from $96,499,063.35, reflecting a rise of 30.2%[49] - Financial expenses decreased by 68.06%, mainly due to changes in exchange gains and losses[22] Other Financial Metrics - The weighted average return on net assets was 3.09%, a decrease of 10.98 percentage points compared to the previous year[9] - The company reported a significant increase in interest income by 195.22%, attributed to the rise in cash and cash equivalents[22] - The company received a VAT refund of 8,033,581.45 RMB, classified as a recurring profit item due to its relevance to normal business operations[22] - The company reported a significant drop in investment income, with a loss of ¥22,024,811.41 in Q1 2022 compared to a gain of ¥377,446,127.41 in Q1 2021[43]

Financial Performance - The company's operating revenue for 2021 was CNY 2,125,862,739.15, representing a year-on-year increase of 51.63%[30]. - The net profit attributable to shareholders for 2021 was CNY 845,035,305.76, a significant increase of 121.82% compared to the previous year[30]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 32.97% to CNY 418,046,340.77 in 2021[30]. - Basic earnings per share for 2021 rose to CNY 2.67, reflecting a year-on-year growth of 122.50%[33]. - The total profit reached 960.87 million RMB, with a year-on-year increase of 126.49%[47]. - The company's cash flow from operating activities decreased by 15.05% to CNY 591,798,010.34 due to increased cash payments for inventory and services[34]. - The gross profit margin decreased to 50.08%, down by 0.51 percentage points due to rising costs of raw materials[163]. Dividend Distribution - The company plans to distribute a cash dividend of 5.0 RMB per 10 shares, totaling approximately 158.2 million RMB, which represents 18.72% of the net profit attributable to shareholders for 2021[7]. - As of December 31, 2021, the total share capital of the company was 317,071,758 shares, with 316,391,758 shares eligible for the dividend after excluding repurchased shares[7]. Research and Development - Research and development expenses accounted for 11.12% of operating revenue in 2021, up from 10.75% in 2020[33]. - R&D expenses amounted to ¥236,307,039.02, representing a 56.79% increase compared to the previous year's ¥150,719,187.87[116]. - The company applied for 269 new patents and obtained 197 authorizations in 2021, totaling 539 patents by the end of December 2021[109]. - The company has established a comprehensive open innovation system, enhancing its competitive edge in the biomedical low-temperature storage and biosafety solution sectors[142]. Market Expansion and User Engagement - The company plans to continue expanding its global market presence and enhancing its product innovation through increased R&D investment[34]. - The company is actively pursuing global market expansion, with multiple products certified by international standards such as NSF/ANSI and DIN[51]. - The company expanded its user base significantly, doubling the number of users in niche areas such as CXO, cell therapy, and gene therapy[49]. - The company is deepening its global market presence by establishing localized teams and systems to better understand and meet user needs, thereby increasing global market share[199]. Operational Risks and Governance - The company has outlined various operational risks and corresponding mitigation measures in the management discussion and analysis section of the report[5]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[10]. - The company has not experienced any violations of decision-making procedures regarding external guarantees[10]. - The company has not disclosed any special arrangements for corporate governance[10]. Technological Advancements - The company has made significant technological advancements, including breakthroughs in automation, microbial culture, environmental simulation, and rapid cooling centrifugation technologies[66]. - The company has developed a comprehensive low-temperature storage solution for biomedical applications, covering sample safety, drug safety, vaccine safety, and blood safety, and has achieved a breakthrough in low-temperature technology, breaking foreign monopolies[66]. - The company launched innovative IoT solutions for blood safety management and vaccine storage, enhancing user experience and supporting the upgrade of the medical industry[93]. Employee and Talent Development - The workforce increased to over 2,000 employees, with 78% of new hires in R&D and marketing roles, strengthening the talent pool[62]. - The company has implemented a diverse employee incentive mechanism, including a restricted stock incentive plan launched in 2021, aimed at attracting and retaining talent[65]. - The company has established a talent reserve pool and a tiered training system to continuously stimulate employee potential and maintain innovation vitality[65]. Compliance and Standards - The company has led or participated in drafting 19 national, industry, and group standards, promoting the standardized development of the industry[66]. - The company participated in the formulation of six national standards, including those for automated low-temperature biological sample banks and vaccine cold chain logistics, establishing industry leadership[114]. Investment and Financial Management - The company’s investment activities resulted in a net cash outflow of CNY 1,501,417,001.14, a significant increase of 1,010.33% compared to the previous year[160]. - The company is actively managing foreign exchange risks through hedging strategies and locking in exchange rates[152]. - The company recognized a gain from the disposal of 17.11% equity in the associate company Mesa during the reporting period[177].

Financial Performance - The company's revenue for Q3 2021 reached ¥592.19 million, representing a year-on-year increase of 53.09%[6] - Net profit attributable to shareholders for Q3 2021 was ¥125.11 million, a 6.41% increase compared to the same period last year[6] - The total revenue for the first three quarters of 2021 was ¥1.52 billion, reflecting a growth of 54.89% year-on-year[6] - Revenue increased by 54.89% driven by high growth in IoT solutions and traditional business[24] - Net profit rose by 155.20% attributed to business scale growth and investment income from disposed joint ventures[24] - The company reported a profit margin increase of 157.99% due to operational scale growth[24] - Total operating revenue for the first three quarters of 2021 reached ¥1,520,143,956.41, a significant increase from ¥981,453,217.89 in the same period of 2020, representing a growth of approximately 54.9%[47] - Net profit for the third quarter of 2021 was ¥700,445,995.03, up from ¥274,465,658.03 in the same quarter of 2020, reflecting a growth of approximately 155.0%[50] - Basic earnings per share for the third quarter of 2021 were ¥2.20, compared to ¥0.86 in the same quarter of 2020, marking an increase of about 156.0%[52] - The company reported a total comprehensive income of ¥724,903,178.40 for the third quarter of 2021, compared to ¥271,656,099.54 in the same quarter of 2020, representing an increase of approximately 167.0%[52] Research and Development - Research and development expenses amounted to ¥81.43 million in Q3 2021, a significant increase of 66.92% year-on-year, accounting for 13.75% of total revenue[9] - Research and development expenses increased by 61.97% due to investments in IoT R&D projects[24] - Research and development expenses for the first three quarters of 2021 were ¥174,004,095.97, up from ¥107,428,279.39 in 2020, reflecting an increase of approximately 62.0%[47] - The company launched new products including a program cooling instrument and a new series of centrifuges, obtaining over 20 related patents[12] Market Performance - The domestic market generated revenue of ¥1.12 billion in the first three quarters, a 66.56% increase year-on-year, driven by IoT solutions[12] - The overseas market revenue reached ¥390.97 million in the first three quarters, showing a growth of 32.79%, with Q3 growth accelerating to 79.15%[12] Cash Flow and Assets - The net cash flow from operating activities for the first three quarters was ¥442.84 million, reflecting an 8.03% increase year-on-year[6] - Cash flow from operating activities for the first three quarters of 2021 was ¥1,829,289,551.15, compared to ¥1,155,364,523.62 in 2020, indicating a growth of about 58.3%[52] - The total assets as of the end of Q3 2021 were ¥4.69 billion, a 19.08% increase compared to the end of the previous year[9] - The company's current assets totaled RMB 3,486,328,814.89, compared to RMB 2,733,965,717.27 in the previous year, indicating a growth of approximately 27.6%[37] - The company's inventory increased significantly to RMB 392,481,243.48, up from RMB 247,949,856.20, representing a growth of approximately 58.2%[37] - The total cash and cash equivalents at the end of the period stood at CNY 799,023,807.51, down from CNY 961,085,040.10 at the end of the previous year[57] Liabilities and Equity - The total liabilities amounted to RMB 2,486,328,814.89, showing an increase from the previous year's liabilities[41] - The total liabilities increased to ¥1,292,765,727.02 in 2021 from ¥1,158,084,744.73 in 2020, representing a growth of approximately 11.5%[43] - Total equity attributable to shareholders reached ¥3,391,034,403.28 in 2021, compared to ¥2,775,877,783.68 in 2020, indicating an increase of about 22.1%[43] - The company reported a significant increase in contract liabilities to RMB 393,869,028.82 from RMB 247,818,290.15, reflecting a growth of about 59%[41] Investment Activities - Cash outflow from investment activities was CNY 6,301,496,005.26, up from CNY 4,213,890,184.72 year-over-year[55] - The net cash flow from investment activities was negative at CNY -1,299,797,346.33, worsening from CNY -768,700,793.76 in the previous year[55] - The company received CNY 4,508,442,851.66 from the recovery of investments, an increase from CNY 3,400,020,000.00 in the previous year[55] - Cash paid for purchasing fixed assets and intangible assets was CNY 140,266,005.26, compared to CNY 55,598,894.72 in the same period last year[55] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,026[27] - The largest shareholder, Qingdao Haier Biomedical Holdings Co., Ltd., holds 31.73% of the shares[27]

Financial Performance - Operating revenue rose by 56.05% to CNY 927,954,150.02 compared to the same period last year[10] - Net profit attributable to shareholders increased by 270.06% to CNY 573,077,466.11 compared to the same period last year[10] - The net profit after deducting non-recurring gains and losses increased by 82.47% to CNY 214,999,373.27 compared to the same period last year[10] - Basic earnings per share increased by 269.39% to CNY 1.81 compared to the same period last year[10] - The weighted average return on equity increased by 12.79 percentage points to 18.93% compared to the same period last year[10] Assets and Shareholder Equity - Total assets increased by 15.38% to CNY 4,548,820,465.63 compared to the end of the previous year[10] - The net assets attributable to shareholders increased by 16.99% to CNY 3,247,598,089.13 compared to the end of the previous year[10] Cash Flow and Expenditure - The net cash flow from operating activities decreased by 6.84% to CNY 216,874,817.07 compared to the same period last year[10] - Research and development expenditure accounted for 9.98% of operating revenue, an increase of 0.12 percentage points compared to the same period last year[10] Shareholder Information - The total number of shareholders reached 10,658 at the end of the reporting period[12]

Financial Performance - Haier Biomedical reported a revenue increase of 25% year-over-year for the first half of 2021, reaching RMB 1.5 billion[19]. - The company achieved a net profit of RMB 300 million, representing a growth of 30% compared to the same period last year[19]. - The company's operating revenue for the first half of the year reached ¥927,954,150.02, representing a year-on-year increase of 56.05%[27]. - Net profit attributable to shareholders increased by 270.06% to ¥573,077,466.11, driven by business scale growth and investment income from the disposal of joint ventures[29]. - Basic earnings per share rose by 269.39% to ¥1.81, reflecting the significant increase in net profit during the reporting period[29]. - The total profit reached 642.41 million yuan, with a significant year-on-year increase of 269.68%[100]. - The company's domestic market revenue reached 671.52 million yuan, representing a year-on-year growth of 76.55%[113]. - The overseas market generated revenue of 236.64 million yuan, with a year-on-year increase of 13.62%[116]. Research and Development - The company is investing RMB 200 million in R&D for new product development, focusing on advanced medical storage solutions[19]. - The company invested 9.98% of its operating revenue in R&D, slightly up from 9.86% in the previous year[29]. - R&D expenses totaled ¥92,569,115, an increase of 57.86% compared to ¥58,640,642 from the previous period[79]. - The number of R&D personnel has increased to 451, representing 24% of the total workforce, with a total R&D personnel compensation of CNY 5.26 million[93]. - The average salary of R&D personnel has risen to CNY 12.36 thousand, compared to CNY 11.69 thousand in the previous period[93]. - The company has accumulated over 448 patents and received more than 10 provincial-level technology awards, with over 20 technical achievements recognized as internationally leading[63]. - The company applied for 140 new patents and obtained 93 patents during the reporting period, bringing the total to 448 patents by the end of June 2021[72]. Market Expansion and Strategy - Haier Biomedical plans to expand its market presence in Southeast Asia, targeting a 20% market share by 2023[19]. - Future guidance indicates a projected revenue growth of 15% for the second half of 2021, driven by new product launches and market expansion[19]. - The company has established a presence in over 120 countries and regions, serving major clients including the Chinese People's Liberation Army General Hospital and Shanghai Ruijin Hospital[37]. - The company is focusing on enhancing its global market presence and expanding overseas sales channels to mitigate risks from industry policy changes[127]. - The company has actively engaged in partnerships with leading universities and research institutions to strengthen its technological advancements and maintain its competitive edge[63]. Product Development and Innovation - Haier Biomedical has launched a new line of solar-powered vaccine refrigerators, aiming to enhance cold chain logistics[19]. - The company has developed innovative IoT solutions for blood safety management and vaccine management, leading to significant advancements in the biomedical industry[36]. - The company has launched innovative IoT solutions for blood safety management and vaccine storage, enhancing user experience and meeting the demand for information and automation[55]. - The company has developed a smart blood management system integrating IoT and RFID technology, improving blood utilization efficiency and safety for patients[71]. - The company has developed a dual-system -30℃ wind-cooled preservation box, enhancing product reliability and reducing temperature fluctuations[69]. Financial Position and Assets - The total assets of the company increased by 15.38% to ¥4,548,820,465.63 compared to the end of the previous year[27]. - The company's cash and cash equivalents decreased to approximately ¥694.65 million as of June 30, 2021, down from ¥1.85 billion at the end of 2020, representing a decline of about 62.5%[196]. - The total current assets increased to approximately ¥3.40 billion as of June 30, 2021, compared to ¥2.73 billion at the end of 2020, reflecting an increase of about 24.3%[196]. - The company's long-term equity investments decreased to approximately ¥109.01 million as of June 30, 2021, down from ¥231.19 million at the end of 2020, a decline of about 52.8%[196]. - The total inventory increased to approximately ¥406.89 million as of June 30, 2021, compared to ¥247.95 million at the end of 2020, indicating an increase of about 63.9%[196]. Corporate Governance and Compliance - Haier Biomedical is committed to maintaining a robust corporate governance structure, ensuring transparency and accountability[8]. - The company has no significant non-operating fund occupation by controlling shareholders or related parties[8]. - The company has outlined measures to stabilize its stock price for three years post-listing, as detailed in the prospectus[159]. - There are no reported violations regarding guarantees or commitments by the company during the reporting period[162]. - The company has made specific commitments regarding the repurchase of shares in the event of fraudulent issuance, as outlined in the prospectus[159]. Risks and Challenges - The company has outlined potential risks in its operations, including market competition and regulatory changes[5]. - The implementation of the "Biological Safety Law" in April 2021 is expected to increase government investment in public health and medical service capabilities, positively impacting the industry[56]. - The company is actively managing foreign exchange risks by entering into hedging agreements and considering RMB settlements to mitigate potential losses from currency fluctuations[127].

Financial Performance - Net profit attributable to shareholders increased by 506.02% to CNY 419,839,546.33 year-on-year[18] - Operating revenue reached CNY 413,627,238.36, representing a year-on-year growth of 55.01%[18] - Total profit amounted to CNY 476,851,880.04, marking a 508.51% increase from CNY 78,363,687.16, driven by growth in operating profit and investment income[39] - The company reported a total comprehensive income of ¥421,148,279.46 for Q1 2021, compared to ¥71,323,889.74 in Q1 2020, an increase of 493%[62] - Basic and diluted earnings per share both stood at CNY 1.32, reflecting a 500.00% increase from CNY 0.22 in the previous year[41] Revenue Growth - Revenue from the vaccine safety segment grew by 107.37%, while blood safety segment revenue surged by 263.53%[20] - Domestic market revenue increased by 48.01%, with IoT solution sales rising by 148.49%[21] - Overseas market revenue grew by 81.16%, with overseas distribution revenue up by 91.32%[22] Cash Flow and Liquidity - Cash flow from operating activities increased by 186.64% to CNY 124,170,918.10 compared to the same period last year[18] - The company reported a net cash flow from operating activities of CNY 124,170,918.10, up 186.64% from CNY 43,320,200.01, attributed to increased cash receipts from sales of goods and services[41] - Cash and cash equivalents decreased by 41.64% to ¥1,078,851,603.37 from ¥1,848,671,180.63, mainly due to investments in financial products[36] Assets and Liabilities - Total assets increased by 15.46% to CNY 4,551,948,540.71 compared to the end of the previous year[18] - Current liabilities rose to CNY 1,237,938,191.13 from CNY 1,044,354,545.25, an increase of about 18.5%[49] - The total liabilities increased to CNY 1,356,161,635.71 from CNY 1,158,084,744.73, reflecting a growth of approximately 17.1%[51] - The company's equity attributable to shareholders rose to CNY 3,186,802,247.17 from CNY 2,775,877,783.68, reflecting an increase of about 14.8%[51] Research and Development - R&D investment accounted for 9.99% of operating revenue, a slight increase of 0.10 percentage points[20] - Research and development expenses increased to CNY 41,339,082.29, a rise of 56.60% from CNY 26,398,022.90, mainly due to increased amortization of intangible assets[39] Shareholder Information - The number of shareholders reached 10,035, with the top ten shareholders holding a significant portion of shares[30] - The largest shareholder, Qingdao Haier Biomedical Holdings, holds 31.73% of shares, totaling 100,591,463 shares[30] Investment Income - The company recorded investment income of CNY 377,446,127.41, a staggering increase of 2,255.28% compared to CNY 16,025,552.92, primarily from government subsidies related to the disposal of joint ventures[39] - The company reported a significant increase in investment income, reaching approximately ¥319.84 million in Q1 2021, compared to ¥13.97 million in Q1 2020[67] Financial Expenses - The company reported a significant decrease in financial expenses, with interest expenses dropping by 80.68% to CNY 1,670,285.47, primarily due to a reduction in deposits[39] - The company’s financial expenses showed a reduction, with interest income of approximately ¥1.22 million in Q1 2021, down from ¥8.45 million in Q1 2020[67] Market Strategy - The company plans to continue expanding its market presence and investing in new technologies to drive future growth, although specific figures were not disclosed in the report[75]

Financial Performance - The company's operating revenue for 2020 was CNY 1,402,028,951.80, representing a year-on-year increase of 38.47% compared to CNY 1,012,520,355.36 in 2019[29]. - The net profit attributable to shareholders for 2020 was CNY 380,954,147.30, a significant increase of 109.24% from CNY 182,061,609.90 in 2019[29]. - The net cash flow from operating activities increased by 148.36% to CNY 696,619,631.33 in 2020, up from CNY 280,486,898.86 in 2019[29]. - The total assets of the company grew by 29.69% to CNY 3,942,599,032.83 at the end of 2020, compared to CNY 3,039,996,721.73 at the end of 2019[29]. - Basic earnings per share for 2020 were CNY 1.20, reflecting a year-on-year increase of 64.38% from CNY 0.73 in 2019[29]. - The company's net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 314,394,795.16, an increase of 87.88% from CNY 167,340,635.12 in 2019[29]. - The company reported a total revenue of 66,559,352.14 RMB for the period, with a significant increase in non-operating income contributing to the overall performance[41]. - The total profit reached 424.24 million yuan, with a year-on-year increase of 100.98%[116]. - The net profit attributable to the parent company was 380.95 million yuan, reflecting a growth of 109.24% year-on-year[116]. Research and Development - The company's R&D investment as a percentage of operating revenue was 10.75% in 2020, a decrease of 1.24 percentage points from 11.99% in 2019[29]. - The total R&D investment for the year was approximately ¥150.72 million, an increase of 24.19% compared to the previous year, with R&D expenses accounting for 10.75% of operating revenue[89]. - The company applied for 168 new patents and obtained 123 authorizations in 2020, totaling 361 patents by year-end[79]. - The company has increased its R&D personnel to 400, representing 27.91% of the total workforce, up from 25.65% in the previous period[106]. - The company’s research and development efforts led to the successful iteration of its CO2 incubators, providing comprehensive solutions for cell preparation[83]. Market Expansion and Strategy - The company reported a significant increase in overseas market expansion contributing to revenue growth, particularly in IoT products[30]. - The company has established a presence in over 120 countries and regions, providing biomedical low-temperature storage solutions and IoT-based safety management systems[44]. - The company has established a domestic distribution network of over 200 and an international network exceeding 400[113]. - The company is actively pursuing market expansion and technological advancements to meet the growing demands of the biomedical sector[88]. - The company has successfully launched multiple new biological safety products and solutions, contributing to its position as a leader in the biological medical low-temperature storage industry[64]. Product Development and Innovation - The company has developed and launched integrated solutions for blood safety management and smart vaccine administration, marking a significant technological advancement[44]. - The company introduced IoT solutions for blood safety management and smart vaccine administration, addressing user needs for information and intelligence upgrades[65]. - The company launched a high-risk specimen transport box that meets WHO and domestic IATA standards within 13 days, ensuring effective pandemic response[82]. - The company developed a smart blood management system based on IoT and RFID technology, significantly improving blood utilization efficiency and safety[84]. - The company launched new products in the vaccine storage category, achieving a temperature stability improvement of 14%[100]. Corporate Governance and Compliance - The audit report issued by Ernst & Young Huaming is a standard unqualified opinion[6]. - The company has not faced any non-operational fund occupation by controlling shareholders or related parties[9]. - There are no violations of decision-making procedures regarding external guarantees[10]. - The company has confirmed that all board members can guarantee the authenticity, accuracy, and completeness of the annual report[11]. - The company has not disclosed any special arrangements for corporate governance[9]. Industry Trends and Outlook - The market for biological safety solutions is expected to expand significantly due to increasing user demand driven by the acceleration of biopharmaceutical innovations and applications[55]. - The Chinese biopharmaceutical market grew from RMB 62.7 billion in 2012 to RMB 262.2 billion in 2018, with a compound annual growth rate of 24.9%[55]. - The introduction of the Biosecurity Law in October 2020 emphasizes the importance of biological safety capacity building, which is expected to positively impact the industry[68]. - The biosecurity sector is projected to benefit from increased government funding and policy support, leading to expanded market opportunities[200]. - The integration of new information technologies such as big data and artificial intelligence is expected to drive growth in the bio-medical sector, addressing user pain points in vaccine and blood safety[200].